Key Recent Program Updates and Upcoming Milestones: FHD-286: AML Update. Foghorn initiated a Phase 1 trial of FHD-286 in combination with decitabine or low-dose cytarabine in relapsed and/or refractory AML patients, with the first patient dosed during the third quarter of 2023. Dose escalation is ongoing with initial clinical data expected in the second half of 2024 . Tyrosine Kinase Inhibitor Resistance. Preclinical data is expected in the second quarter of 2024. FHD-909: Dosing of first patient in Phase 1 trial for FHD-909 in BRG1-mutated NSCLC is expected in the second half of 2024. Drug Discovery Platform: Potential for five additional INDs in the next four years.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
- Foghorn Therapeutics, Inc. (FHTX) Q1 Earnings Cheat Sheet
- Foghorn Therapeutics Appoints Kristian Humer as New CFO
- Foghorn Therapeutics appoints Humer as Chief Financial Officer
- Foghorn Therapeutics Unveils Cancer Research Breakthroughs
